P
P

Philips

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Financial Times - Aug 17

Aug 17 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - Liz Truss and Rishi Sunak rule out second Scottish independence vote Link - UK launches legal proceedings against EU over access to Horizon programme Link - AstraZeneca sues former executive over move to rival GSK Link - Philips chief exits in wake of fallout from medical device recall Link Overview - Foreign secretary Liz Truss, f
A
G
P

Philips Successfully Prices Offering Of Notes For EUR 2 Bln

April 28 (Reuters) - Koninklijke Philips NV PHG.AS : * PHILIPS SUCCESSFULLY PRICES OFFERING OF NOTES FOR EUR 2 BILLION * PRICING OF ITS ISSUE OF EUR 750 MILLION FIXED RATE NOTES DUE 2027 * KONINKLIJKE PHILIPS -PRICING OF ITS ISSUE OF EUR 650 MILLION GREEN INNOVATION NOTES DUE 2029 AND EUR 600 MILLION SUSTAINABILITY INNOVATION NOTES DUE 2033 * ISSUE
P

European shares buoyed by commodity stocks on China stimulus hopes

* Tech stocks extend rally * Miners buoyant on China stimulus hopes * Just Eat Takeaway maintains 2022 targets * STOXX 600 Q4 earnings expected to rise 48.5% (Updates with market close) By Anisha Sircar and Ambar Warrick Jan 12 (Reuters) - European shares ended higher on Wednesday, supported by commodity-linked stocks which rose on hopes of more stimulus in major importer China, while easing bond yields took pressure off the technology sector.
P
S
E
F
U
G

U.S. rushed contracts to 19 suppliers with troubled plants

(For more Reuters Special Reports, click on ) (Updates with additional FDA comment) By Marisa Taylor WASHINGTON, Dec 2 (Reuters) - As the Trump administration debated whether to declare COVID-19 a national emergency early last year, a little-known U.S. health office issued a public plea to Big Pharma. On March 6, 2020, the Biomedical Advanced Research and Development Authority called on pharmaceutical and medical device companies to develop a vast array of essential COVID supplies.
P
D
S

U.S. rushed contracts to 19 suppliers with troubled plants

(For more Reuters Special Reports, click on ) By Marisa Taylor WASHINGTON, Dec 2 (Reuters) - As the Trump administration debated whether to declare COVID-19 a national emergency early last year, a little-known U.S. health office issued a public plea to Big Pharma. On March 6, 2020, the Biomedical Advanced Research and Development Authority called on pharmaceutical and medical device companies to develop a vast array of essential COVID supplies.
P
D
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.